Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07764003
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHsHangzhou Highlightll Pharmaceutical Co., LtdNot Yet RecruitingPhase 2
NCT07764003Not Yet Recruiting
Phase 2
A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Re...Hangzhou Highlightll Phar...
NCT07762443
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia AreataJiangsu vcare pharmaceutical technology co., LTDNot Yet RecruitingPhase 1
NCT07762443Not Yet Recruiting
Phase 1
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Are...Jiangsu vcare pharmaceuti...
NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762703Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metasta...BreakBio Corp
NCT07763067
Acceptability and Outcomes of an Online Parent-Mediated Intervention for Young Autistic ChildrenHerguner Therapy Private ClinicCompletedNot Applicable
NCT07763067Completed
Not Applicable
Acceptability and Outcomes of an Online Parent-Mediated Intervention for Young A...Herguner Therapy Private...
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302Idorsia Pharmaceuticals Ltd.Unknown
NCT07762638Unknown
—
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated...Idorsia Pharmaceuticals L...
NCT07762716
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyBreakBio CorpNot Yet RecruitingPhase 1
NCT07762716Not Yet Recruiting
Phase 1
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTr...BreakBio Corp
NCT07762001
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MDActive Not RecruitingPhase 1
NCT07762001Active Not Recruiting
Phase 1
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MD
NCT07762820
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder TumorsLudwig-Maximilians - University of MunichNot Yet RecruitingNot Applicable
NCT07762820Not Yet Recruiting
Not Applicable
REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retr...Ludwig-Maximilians - Univ...
NCT07762924
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryFudan UniversityRecruitingPhase 2
NCT07762924Recruiting
Phase 2
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Fol...Fudan University
NCT07762014
rBCG-N-RSV Vaccine in Adults Aged 60 Years and OlderBiothervax SpANot Yet RecruitingPhase 2
NCT07762014Not Yet Recruiting
Phase 2
rBCG-N-RSV Vaccine in Adults Aged 60 Years and OlderBiothervax SpA
NCT07762794
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent RepairHumacyte, Inc.Not Yet RecruitingPhase 4
NCT07762794Not Yet Recruiting
Phase 4
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real Worl...Humacyte, Inc.
NCT07764250
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training in Elderly With Mild and Moderate Cognitive ImpairmentShifa Tameer-e-Millat UniversityRecruitingNot Applicable
NCT07764250Recruiting
Not Applicable
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training i...Shifa Tameer-e-Millat Uni...
NCT07763795
Effects of BFRT on Glycemic Control, Nerve Conduction, Functional Outcomes and QOL in Individuals With Type 2 DiabetesSuperior UniversityActive Not RecruitingNot Applicable
NCT07763795Active Not Recruiting
Not Applicable
Effects of BFRT on Glycemic Control, Nerve Conduction, Functional Outcomes and Q...Superior University
NCT07764185
Caring Recharge Project for Caregivers of Individuals With Alzheimer's DiseasePhotozig, Inc.Not Yet RecruitingPhase 2
NCT07764185Not Yet Recruiting
Phase 2
Caring Recharge Project for Caregivers of Individuals With Alzheimer's DiseasePhotozig, Inc.
NCT07764081
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, Nanjing Medical UniversityRecruiting
NCT07764081Recruiting
—
Progression, Management, and Clinical Outcomes of Coronary Artery AneurysmsNanjing First Hospital, N...
NCT07763405
Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic StrokeThe First Affiliated Hospital of Nanchang UniversityNot Yet RecruitingPhase 4
NCT07763405Not Yet Recruiting
Phase 4
Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic StrokeThe First Affiliated Hosp...
NCT07763496
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUPNot Yet RecruitingPhase 2
NCT07763496Not Yet Recruiting
Phase 2
Relacorilant and Nab-Paclitaxel in Recurrent or Metastatic Cervical CancerARCAGY/ GINECO GROUP
NCT07762222
Outcomes of Iliac Vein Stenting With Dedicated Venous Stents in Treatment of Chronic Post-thrombotic Venous UlcersAin Shams UniversityRecruitingNot Applicable
NCT07762222Recruiting
Not Applicable
Outcomes of Iliac Vein Stenting With Dedicated Venous Stents in Treatment of Chr...Ain Shams University
NCT07763171
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal AdenocarcinomaGruppo Oncologico del Nord-OvestNot Yet RecruitingPhase 3
NCT07763171Not Yet Recruiting
Phase 3
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-neg...Gruppo Oncologico del Nor...
Result Breakdown
Not yet recruiting12 (60%)
Recruiting4 (20%)
Active, not recruiting2 (10%)
Completed1 (5%)
Unknown1 (5%)
not_applicable6 (30%)
Phase 25 (25%)
Phase 14 (20%)
Not Specified2 (10%)
Phase 42 (10%)
Phase 31 (5%)